C07K 2317/35
Valency
C07K2317/35 (Valency) appears on 825 US grants and 1,891 published applications in this corpus.
Search patents in C07K- Granted patents
- 825
- Published applications
- 1,891
- Assignees
- 627
- Inventors
- 3,741
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 1 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 3 |
| 2007 | 0 | 1 |
| 2008 | 1 | 2 |
| 2009 | 0 | 6 |
| 2010 | 2 | 11 |
| 2011 | 3 | 10 |
| 2012 | 2 | 24 |
| 2013 | 7 | 40 |
| 2014 | 18 | 65 |
| 2015 | 40 | 57 |
| 2016 | 49 | 112 |
| 2017 | 48 | 134 |
| 2018 | 56 | 105 |
| 2019 | 65 | 87 |
| 2020 | 67 | 143 |
| 2021 | 72 | 137 |
| 2022 | 72 | 185 |
| 2023 | 64 | 175 |
| 2024 | 94 | 237 |
| 2025 | 100 | 215 |
| 2026 | 64 | 141 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Bispecific antibody simultaneously binding to interleukin-4 receptor alpha subunit and interleukin-5 receptor alpha subunit, encoding nucleic acids thereof and methods of use thereof for treatment29 Sep 2026US 12,747,297 B2Ajou University Industry-Academic Cooperation Foundation
- Multi-specific antibodies binding to BCMA29 Sep 2026US 12,747,298 B2TeneoBio, Inc.
- Monoclonal antibody inhibiting SMIM15 and application thereof15 Sep 2026US 12,735,474 B2Affiliated Hospital of Nantong University
- Bispecific antigen binding molecules targeting OX40 and FAP15 Sep 2026US 12,735,485 B2Hoffmann-La Roche Inc.
- Immunoglobulin variable domains1 Sep 2026US 12,723,072 B2Ablynx N. V.
- High-affinity t cell receptor for identifying kras mutation and use thereof1 Oct 2026US 2026/0297159 A1Xlifesc, Ltd.
- Antibodies targeting s100 proteins and uses thereof1 Oct 2026US 2026/0297172 A1Albert Einstein College of Medicine
- Anti-il-13 long-acting nanobody sequence and applications thereof1 Oct 2026US 2026/0297175 A1Shanghai Novamab Biopharmaceuticals Co., Ltd.
- Novel EGFR Binding Proteins1 Oct 2026US 2026/0297200 A1
- Growth hormone targeting polypeptides1 Oct 2026US 2026/0297205 A1The University of Chicago
Most cited
By later US patents
- Anti-C5 antibodies having improved pharmacokinetics89US 9,079,949 B1Alexion Pharmaceuticals, Inc. · 2015
- Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof84US 9,657,102 B2Regeneron Pharmaceuticals, Inc. · 2017
- Heterodimeric antibodies to CD3 X CD12370US 9,856,327 B2Xencor, Inc. · 2018
- Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases67US 8,420,086 B2Immunomedics, Inc. · 2013
- Dual variable domain immunoglobulins and uses thereof65US 8,735,546 B2AbbVie Inc. · 2014